255
Participants
Start Date
June 30, 2010
Primary Completion Date
November 30, 2017
Study Completion Date
November 30, 2017
Plitidepsin
plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
Dexamethasone
4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
1107, Tuscaloosa
1103, Los Angeles
1105, Jacksonville
1102, New York
1104, Canton
108, Adelaide
102, Canberra
101, Geelong
105, Parkville
106, Perth
104, South Brisbane
109, Woodville
202, Graz
204, Innsbruck
203, Salzburg
201, Vienna
205, Vienna
208, Vienna
304, Bruges
301, Brussels
303, Brussels
302, Ghent
502, Brno
503, Hradec Králové
501, Prague
601, Lille
602, Nantes
606, Rouen
604, Vandœuvre-lès-Nancy
709, Düsseldorf
705, Essen
706, Frankfurt
707, Frankfurt
708, Freiburg im Breisgau
703, Heidelberg
702, München
704, Würzburg
1301, Athens
1303, Pátrai
1302, Thessaloniki
1401, Dublin
806, Bari
801, Genova
805, Reggio Emilia
803, Rozzano
804, San Giovanni Rotondo
802, Torino
901, Rotterdam
902, Rotterdam
1601, Christchurch
1602, Takapuna
1704, Opole
1703, Warsaw
1802, Braga
1801, Porto
2001, San Juan
1502, Anyang
1501, Daejeon
1507, Hwasun
1506, Incheon
1505, Jeonju
1508, Seongnam
1503, Seoul
1504, Seoul
1509, Seoul
1201, Barcelona
1203, Barcelona
1209, Barcelona
1207, Madrid
1210, Madrid
1206, Murcia
1204, Palma de Mallorca
1208, Salamanca
1202, San Sebastián
1205, Valencia
1901, Taipei
1902, Taipei
1903, Taipei
1003, Bournemouth
1004, Bradford
1001, London
1005, Nottingham
Lead Sponsor
PharmaMar
INDUSTRY